BioSpace News Archive

Business

Slow Start? Vesalius Axes 43% of Staff 6 Months After Launch

Six months after its launch, Vesalius Therapeutics is laying off 43% of its staff. With a current staff of 67, the company is slashing 29 jobs.

September 20, 2022
·
2 min read
·
Mark Terry
Drug Development

First Wave Embarks on Take Two in CF and Chronic Pancreatitis EPI

First Wave BioPharma announced that it is restarting its adrulipase program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.

September 20, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Wave Presents Promising Biomarker Data in Huntington’s Disease

Wave Life Sciences presented promising early data from its Phase Ib/IIa SELECT-HD trial in Huntington’s disease with evidence of biomarker improvements.

September 20, 2022
·
2 min read
·
Mark Terry
Business

Rocket Fuels AAV Cardiac Portfolio with Renovacor Buy

Shares of Renovacor, Inc. stock are surging in premarket trading following Rocket Pharmaceuticals’ announcement it will acquire the company in an all-stock transaction valued at $53 million.

September 20, 2022
·
2 min read
·
Alex Keown
Drug Development

Alzheon Biomarker Trial Brings Insight to Stalled Treatment Space

Alzheon Inc. unveiled promising data from a Phase II biomarker trial of its investigational drug ALZ-801 to treat early Alzheimer’s disease.

September 20, 2022
·
1 min read
·
Paul Elias
Policy

Biden Declares ‘COVID-19 Pandemic Over’ as Biopharma Reacts (Updated)

Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.

September 20, 2022
·
2 min read
·
Alex Keown
Business

PepGen’s Michelle Mellion is Redefining Success in Clinical Development

Beyond the usual challenge of delivering high-quality data that answers meaningful questions, PepGen’s Michelle Mellion is dedicated to “incorporating the patient’s voice into everything we do.”

September 20, 2022
·
5 min read
·
Gail Dutton
Policy

FDA Advisory Committee Votes Against Recommending Spectrum’s NSCLC Drug - Updated

Shares of Spectrum Pharmaceuticals plunged 33% upon the release of briefing documents for an FDA advisory meeting regarding poziotinib

September 20, 2022
·
3 min read
·
Mark Terry
Drug Development

AVROBIO’s Cystinosis Gene Therapy Snags Rare Pediatric Designation

The FDA granted rare pediatric disease designation to AVR-RD-04, an experimental gene therapy treatment for the lysosomal storage disease cystinosis, AVROBIO announced Tuesday.

September 20, 2022
·
2 min read
·
Alex Keown
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

Addex Therapeutics announced that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.

September 20, 2022
·
4 min read